{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["lutetium lu 177 vipivotide tetraxetan"]],"indication":"metastatic castration-resistant prostate cancer","name":"RE-LuPSMA","nct_id":"NCT06288113","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=re-lupsma-nct06288113. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive 177Lu-PSMA-617 IV on day 1 of each cycle. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive gallium Ga 68 gozetotide IV and undergo PET/CT at screening and on study, undergo SPECT/CT on study, and undergo collection of blood samples throughout the trial.","label":"Treatment (177Lu-PSMA-617)","type":"EXPERIMENTAL"}],"collaborators":["Novartis Pharmaceuticals"],"completion_date":{"date":"2028-01-27","type":"ESTIMATED"},"conditions":["Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":{"count":40,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","CT","CT Scan","tomography"],"type":"PROCEDURE"},{"name":"Gallium Ga 68 Gozetotide","otherNames":["(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC","(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC","(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC","(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC","(68Ga)Glu-urea-Lys(Ahx)-HBED-CC","68Ga-DKFZ-PSMA-11","68Ga-HBED-CC-PSMA","68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC","68Ga-PSMA","68Ga-PSMA-11","68Ga-PSMA-HBED-CC","[68Ga] Prostate-specific Membrane Antigen 11","[68Ga]GaPSMA-11","AAA 517","AAA-517","AAA517","Ga PSMA","Ga-68 labeled DKFZ-PSMA-11","Ga-68 labeled PSMA-11","GA-68 PSMA-11","Gallium Ga 68 PSMA-11","Gallium Ga 68-labeled PSMA-11","GALLIUM GA-68 GOZETOTIDE","Gallium-68 PSMA","Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC","GaPSMA","PSMA-HBED-CC GA-68"],"type":"OTHER"},{"name":"Lutetium Lu 177 Vipivotide Tetraxetan","otherNames":["177Lu-labeled PSMA-617","177Lu-PSMA-617","AAA 617","AAA-617","AAA617","Lu177-PSMA-617","Lutetium Lu 177-PSMA-617","LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN","Lutetium-177-PSMA-617","Pluvicto"],"type":"DRUG"},{"name":"Positron Emission Tomography","otherNames":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","proton magnetic resonance spectroscopic imaging","PT"],"type":"PROCEDURE"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"},{"name":"Single Photon Emission Computed Tomography","otherNames":["Medical Imaging, Single Photon Emission Computed Tomography","Single Photon Emission Tomography","Single-Photon Emission Computed","single-photon emission computed tomography","SPECT","SPECT imaging","SPECT SCAN","SPET","ST","tomography, emission computed, single photon","Tomography, Emission-Computed, Single-Photon"],"type":"PROCEDURE"}],"last_update":"2026-03-13","lead_sponsor":"Jonsson Comprehensive Cancer Center","official_title":"Re-Treatment With 177Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer: A Prospective Phase 2 Trial (RE-LuPSMA STUDY)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-01-27","type":"ESTIMATED"},"primary_outcomes":[{"measure":"12-month overall survival","timeFrame":"Assessed at 12 months"}],"references":[{"citation":"Nikitas J, Holzgreve A, Juarez J, Kimura K, Lira S, Alam H, Contreras M, Theus L, Nguyen AT, Ells Z, Zhu S, Grogan T, Elashoff DA, Unterrainer LM, Dahlbom M, Allen-Auerbach M, Czernin J, Calais J. Phase 2 Prospective Trial of Retreatment with [177Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA. J Nucl Med. 2026 May 1;67(5):674-680. doi: 10.2967/jnumed.125.271231.","pmid":"41679923","type":"DERIVED"}],"start_date":{"date":"2024-08-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial","url":"https://clinicaltrials.gov/study/NCT06288113"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/re-lupsma-nct06288113"}